Could better dosing save critically ill kids?
NCT ID NCT02539407
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is looking at how anti-infective drugs work in critically ill children. The goal is to find the right doses for each child to improve treatment and reduce risks. Researchers will collect blood samples and health data from 3000 children in intensive care or immuno-hematology units.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to safer, more effective dosing guidelines for anti-infectives in critically ill children.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly change practice, and results depend on complex data analysis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2015
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Minor patients requiring the administration of anti-infectives
- Ages
-
1 day to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Minor patient requiring the administration of an anti-infective belonging to the following classes : β-lactam antibiotics; aminoglycosides, glycopeptides; fluoroquinolones; other antibiotics (daptomycin, rifampin, trimethoprim, sulfamethoxazole, clarithromycin); fungal; antivirals, during its follow-up or hospitalization Exclusion Criteria: * Patient and parents having notified to the doctor that they refuse data recovery.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pediatric immuno-hematology department are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hospital Necker - Enfants Malades (Public Hospitals of Paris)
RECRUITINGParis, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Video vs. booklet: which training eases Mothers' stress in the ICU?
- A simple urine test and a smart alert may help predict kidney failure in sick kids
- Simple sleep aids tested for kids in intensive care
- New study aims to give ICU kids a voice in their recovery
- Mom's voice and weighted blanket may ease Kids' ICU fears
- Simple sleep aids may cut delirium and pain in hospitalized kids